<p>Disc Medicine, Inc.（納斯達克代碼：IRON - 免費報告）- HC Wainwright 的股票分析師在 5 月 6 日星期三向客户和投資者發佈的研究報告中上調了 Disc Medicine 的 2030 財年每股收益（EPS）預期。HC Wainwright 分析師 D. Tsao 現在預計該公司將實現每股收益 7.40 美元，高於之前預測的 7.12 美元。Disc Medicine 當前全年的共識預期收益為每股（6.68 美元）。</p>
<p>獲取 <strong>Disc Medicine</strong> 警報：</p>
<p>Disc Medicine（納斯達克代碼：IRON - 獲取免費報告）在 5 月 5 日星期二發佈了季度財報。該公司報告季度每股收益（EPS）為（1.65 美元），低於共識預期的（1.62 美元）3 美分。</p>
<p>其他研究分析師最近也發佈了關於該股票的報告。富國銀行將 Disc Medicine 的目標股價從 78.00 美元上調至 79.00 美元，並在 3 月 2 日的報告中給予該股票 “超配” 評級。摩根士丹利在 2 月 17 日的報告中將 Disc Medicine 的目標股價設定為 75.00 美元。Cantor Fitzgerald 在 2 月 17 日的報告中將 Disc Medicine 的目標股價從 153.00 美元下調至 125.00 美元，並給予該公司 “超配” 評級。Weiss Ratings 在 4 月 20 日的報告中重新發布了 Disc Medicine 的 “賣出（d-）” 評級。最後，Raymond James Financial 在 1 月 15 日的研究報告中重申了 Disc Medicine 的 “市場表現” 評級。十位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 104.80 美元。</p>
<p><strong>閲讀我們最新的 Disc Medicine 股票分析</strong></p>
<h2>Disc Medicine 股價上漲 1.6%</h2>
<p>納斯達克 IRON 在星期四開盤價為 68.65 美元。該股票的市值為 26.2 億美元，市盈率為-10.37，貝塔值為 0.93。Disc Medicine 的 52 周低點為 40.00 美元，52 周高點為 99.50 美元。該公司的 50 日移動平均價格為 65.01 美元，200 日移動平均價格為 76.09 美元。該公司的速動比率為 21.94，流動比率為 21.94，債務與股本比率為 0.04。</p>
<h2>Disc Medicine 的機構交易</h2>
<p>一些對沖基金最近買入和賣出了該公司的股票。RA Capital Management L.P.在第四季度將其在 Disc Medicine 的持股增加了 25.3%。RA Capital Management L.P.現在擁有 1,976,132 股該公司的股票，價值 156,925,000 美元，此前在上個季度額外購買了 399,026 股。先鋒集團在第四季度將其在 Disc Medicine 的持股增加了 22.1%。先鋒集團現在擁有 1,767,680 股該公司的股票，價值 140,371,000 美元，此前在該期間額外購買了 319,621 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Disc Medicine 的持股增加了 28.0%。Price T Rowe Associates Inc. MD 現在擁有 1,698,005 股該公司的股票，價值 134,839,000 美元，此前在該期間額外購買了 371,576 股。摩根大通在第四季度將其在 Disc Medicine 的持股增加了 110.0%。摩根大通現在擁有 1,581,127 股該公司的股票，價值 125,557,000 美元，此前在該期間額外購買了 828,248 股。最後，威靈頓管理集團在第四季度將其在 Disc Medicine 的持股增加了 7.7%。威靈頓管理集團現在擁有 1,518,274 股該公司的股票，價值 120,566,000 美元，此前在該期間額外購買了 108,197 股。機構投資者和對沖基金持有該公司 83.70% 的股票。</p>
<h2>內部活動</h2>
<p>在相關消息中，首席財務官 Jean M. Franchi 在 4 月 14 日星期二出售了 6,257 股該公司的股票。股票以平均價格 69.24 美元出售，總交易額為 433,234.68 美元。出售後，首席財務官在公司中持有 64,333 股，價值約為 4,454,416.92 美元。此交易代表其持股減少了 8.86%。該出售在與證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，內部人士 Pamela Stephenson 在 2 月 17 日星期二出售了 5,531 股該公司的股票。股票以平均價格 62.86 美元出售，總交易額為 347,678.66 美元。出售後，內部人士在公司中持有 80,998 股，價值約為 5,091,534.28 美元。此交易代表其持股減少了 6.39%。有關此出售的更多詳細信息可在官方 SEC 披露中找到。內部人士在過去 90 天內出售了 59,410 股公司股票，價值 3,840,013 美元。內部人士持有該公司 3.64% 的股票。</p>
<h2>Disc Medicine 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Disc Medicine, Inc. 納斯達克：IRON 是一家臨牀階段的生物技術公司，專注於發現和開發精準醫學，以恢復嚴重遺傳和獲得性疾病中的正常細胞功能。該公司採用以化學為驅動的方法，識別選擇性調節 RNA 結合蛋白或剪接調控通路的小分子。通過利用專有的篩選和藥物化學平台，Disc Medicine 旨在解決具有高度未滿足醫療需求和有限治療選擇的疾病。</p>
<p>該公司的產品線以針對神經肌肉和血液疾病的主要項目為基礎。</p>
<h2>另見</h2>
<ul>
<li>我們更喜歡的五隻股票超過 Disc Medicine</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Disc Medicine 嗎？</h2>
<p>在考慮 Disc Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Disc Medicine 並不在名單上。</p>
<p>雖然 Disc Medicine 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IRON

<p>Disc Medicine, Inc.（納斯達克代碼：IRON）其 2030 財年每股收益（EPS）預測被 HC Wainwright 從 7.12 美元上調至 7.40 美元。該公司報告的季度每股收益為（1.65 美元），未能達到預期。分析師的目標價格各不相同，富國銀行將其目標價上調至 79.00 美元。該股票目前的共識評級為 “適度買入”，交易價格為 68.65 美元，市值為 26.2 億美元。機構投資者持有該股票的 83.70%，並且最近有內部人士出售股票的報告</p>

<p>Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at HC Wainwright upped their FY2030 EPS estimates for Disc Medicine in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $7.40 per share for the year, up from their previous forecast of $7.12. The consensus estimate for Disc Medicine's current full-year earnings is ($6.68) per share.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.（納斯達克代碼：IRON - 免費報告）- HC Wainwright 的股票分析師在 5 月 6 日星期三向客户和投資者發佈的研究報告中上調了 Disc Medicine 的 2030 財年每股收益（EPS）預期。HC Wainwright 分析師 D. Tsao 現在預計該公司將實現每股收益 7.40 美元，高於之前預測的 7.12 美元。Disc Medicine 當前全年的共識預期收益為每股（6.68 美元）。</p>
</div><p>Get <strong>Disc Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Disc Medicine</strong> 警報：</p>
</div><p>Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03).</p>
<div class="lb-trans"><p>Disc Medicine（納斯達克代碼：IRON - 獲取免費報告）在 5 月 5 日星期二發佈了季度財報。該公司報告季度每股收益（EPS）為（1.65 美元），低於共識預期的（1.62 美元）3 美分。</p>
</div><p>Other research analysts have also recently issued reports about the stock. Wells Fargo &amp; Company increased their price target on shares of Disc Medicine from $78.00 to $79.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, March 2nd. Morgan Stanley set a $75.00 price target on shares of Disc Medicine in a report on Tuesday, February 17th. Cantor Fitzgerald cut their price target on shares of Disc Medicine from $153.00 to $125.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, February 17th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Disc Medicine in a report on Monday, April 20th. Finally, Raymond James Financial restated a &#34;market perform&#34; rating on shares of Disc Medicine in a research report on Thursday, January 15th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $104.80.</p>
<div class="lb-trans"><p>其他研究分析師最近也發佈了關於該股票的報告。富國銀行將 Disc Medicine 的目標股價從 78.00 美元上調至 79.00 美元，並在 3 月 2 日的報告中給予該股票 “超配” 評級。摩根士丹利在 2 月 17 日的報告中將 Disc Medicine 的目標股價設定為 75.00 美元。Cantor Fitzgerald 在 2 月 17 日的報告中將 Disc Medicine 的目標股價從 153.00 美元下調至 125.00 美元，並給予該公司 “超配” 評級。Weiss Ratings 在 4 月 20 日的報告中重新發布了 Disc Medicine 的 “賣出（d-）” 評級。最後，Raymond James Financial 在 1 月 15 日的研究報告中重申了 Disc Medicine 的 “市場表現” 評級。十位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 104.80 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Disc Medicine</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 Disc Medicine 股票分析</strong></p>
</div><h2>Disc Medicine Trading Up 1.6%</h2>
<div class="lb-trans"><h2>Disc Medicine 股價上漲 1.6%</h2>
</div><p>NASDAQ IRON opened at $68.65 on Thursday. The stock has a market capitalization of $2.62 billion, a P/E ratio of -10.37 and a beta of 0.93. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The firm has a 50-day moving average price of $65.01 and a 200 day moving average price of $76.09. The company has a quick ratio of 21.94, a current ratio of 21.94 and a debt-to-equity ratio of 0.04.</p>
<div class="lb-trans"><p>納斯達克 IRON 在星期四開盤價為 68.65 美元。該股票的市值為 26.2 億美元，市盈率為-10.37，貝塔值為 0.93。Disc Medicine 的 52 周低點為 40.00 美元，52 周高點為 99.50 美元。該公司的 50 日移動平均價格為 65.01 美元，200 日移動平均價格為 76.09 美元。該公司的速動比率為 21.94，流動比率為 21.94，債務與股本比率為 0.04。</p>
</div><h2>Institutional Trading of Disc Medicine</h2>
<div class="lb-trans"><h2>Disc Medicine 的機構交易</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. boosted its position in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after acquiring an additional 399,026 shares during the last quarter. Vanguard Group Inc. raised its stake in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. JPMorgan Chase &amp; Co. raised its stake in Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase &amp; Co. now owns 1,581,127 shares of the company's stock worth $125,557,000 after purchasing an additional 828,248 shares during the period. Finally, Wellington Management Group LLP raised its stake in Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company's stock worth $120,566,000 after purchasing an additional 108,197 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近買入和賣出了該公司的股票。RA Capital Management L.P.在第四季度將其在 Disc Medicine 的持股增加了 25.3%。RA Capital Management L.P.現在擁有 1,976,132 股該公司的股票，價值 156,925,000 美元，此前在上個季度額外購買了 399,026 股。先鋒集團在第四季度將其在 Disc Medicine 的持股增加了 22.1%。先鋒集團現在擁有 1,767,680 股該公司的股票，價值 140,371,000 美元，此前在該期間額外購買了 319,621 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Disc Medicine 的持股增加了 28.0%。Price T Rowe Associates Inc. MD 現在擁有 1,698,005 股該公司的股票，價值 134,839,000 美元，此前在該期間額外購買了 371,576 股。摩根大通在第四季度將其在 Disc Medicine 的持股增加了 110.0%。摩根大通現在擁有 1,581,127 股該公司的股票，價值 125,557,000 美元，此前在該期間額外購買了 828,248 股。最後，威靈頓管理集團在第四季度將其在 Disc Medicine 的持股增加了 7.7%。威靈頓管理集團現在擁有 1,518,274 股該公司的股票，價值 120,566,000 美元，此前在該期間額外購買了 108,197 股。機構投資者和對沖基金持有該公司 83.70% 的股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, CFO Jean M. Franchi sold 6,257 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the sale, the chief financial officer owned 64,333 shares in the company, valued at approximately $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Pamela Stephenson sold 5,531 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the sale, the insider owned 80,998 shares in the company, valued at approximately $5,091,534.28. This trade represents a 6.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 59,410 shares of company stock valued at $3,840,013 in the last 90 days. Insiders own 3.64% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Jean M. Franchi 在 4 月 14 日星期二出售了 6,257 股該公司的股票。股票以平均價格 69.24 美元出售，總交易額為 433,234.68 美元。出售後，首席財務官在公司中持有 64,333 股，價值約為 4,454,416.92 美元。此交易代表其持股減少了 8.86%。該出售在與證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，內部人士 Pamela Stephenson 在 2 月 17 日星期二出售了 5,531 股該公司的股票。股票以平均價格 62.86 美元出售，總交易額為 347,678.66 美元。出售後，內部人士在公司中持有 80,998 股，價值約為 5,091,534.28 美元。此交易代表其持股減少了 6.39%。有關此出售的更多詳細信息可在官方 SEC 披露中找到。內部人士在過去 90 天內出售了 59,410 股公司股票，價值 3,840,013 美元。內部人士持有該公司 3.64% 的股票。</p>
</div><h2>Disc Medicine Company Profile</h2>
<div class="lb-trans"><h2>Disc Medicine 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.</p>
<div class="lb-trans"><p>Disc Medicine, Inc. 納斯達克：IRON 是一家臨牀階段的生物技術公司，專注於發現和開發精準醫學，以恢復嚴重遺傳和獲得性疾病中的正常細胞功能。該公司採用以化學為驅動的方法，識別選擇性調節 RNA 結合蛋白或剪接調控通路的小分子。通過利用專有的篩選和藥物化學平台，Disc Medicine 旨在解決具有高度未滿足醫療需求和有限治療選擇的疾病。</p>
</div><p>The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.</p>
<div class="lb-trans"><p>該公司的產品線以針對神經肌肉和血液疾病的主要項目為基礎。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Disc Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 Disc Medicine</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=IRON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Disc Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Disc Medicine 嗎？</h2>
</div><p>Before you consider Disc Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Disc Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Disc Medicine 並不在名單上。</p>
</div><p>While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Disc Medicine 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 上調了 Disc Medicine 2030 財年的每股收益預測